Background: Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with advanced stage disease. An accurate prediction model is important to ascertain the prognosis of HCC patients treated with sorafenib. This study aimed to predict the outcome of HCC patients treated with sorafenib using ACLR and HALP scores. Methods: This Observational Retrospective Cohort Study was conducted on 110 Patients with HCC patients from January 2015 to December 2022 at Medical Oncology Department, Faculty of Medicine, Zagazig University. Results: HALP and ACLR score were significantly associated with treatment outcome among HCC patients treated with sorafenib. HALP was a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 42.9 with sensitivity of 75.7% and specificity of 86.3%. ACLR was a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 75.6 with sensitivity of 78.4% and specificity of 82.2%. High HALP score indicates better prognosis with a cut off of 42.9. Low ACLR indicates better prognosis with a cut of 75.6. Conclusion: Both HALP and ACLR scores can be used as valid prognostic scores for independently predicting the overall prognosis in HCC patients treated with Sorafenib. Having a low HALP score indicates worse prognosis, while, our results showed that the cut off for ACLR 75.6 .. but high and low score didn't show any significance in predicting the PFS or OS but they show significant sensitivity and specificit